Loading
Life sciences · Journal article
Journal of Clinical Investigation · August 11, 2026
Encouraging direction, but not yet definitive.
A preclinical study combining CRISPR screening, cell biology, and patient-derived xenograft models identifies FAK (PTK2) as a potential therapeutic target in chromosome 8 gain MPNSTs and demonstrates that combined FAK and MEK inhibition suppresses tumor growth in vivo more effectively than single agents. This provides mechanistic rationale for clinical investigation but does not yet constitute evidence of human clinical benefit.
CRISPR knockout screen with mechanistic cell biology and patient-derived xenograft efficacy study. MPNST cell lines (presumed NF1-deficient) and patient-derived xenografts, including those with chromosome 8 gain.. Intervention: FAK inhibitor (small molecule) alone or combined with RAF/MEK inhibitor; genetic FAK inhibition also tested.. Compared with: Single-agent FAKi; single-agent RAF/MEKi; untreated control implied..
CRISPR knockout screen identified 58 essential genes on chr8, including PTK2 (FAK) Both pharmacological and genetic FAK inhibition reduced MPNST cell proliferation in vitro and tumor growth in vivo Combined FAKi and RAF/MEKi treatment increased cleaved caspase-3 and PARP-1, indicating enhanced apoptosis
Both pharmacological and genetic FAK inhibition reduced MPNST cell proliferation in vitro and tumor growth in vivo
This work provides preclinical justification for testing combined FAK/MEK inhibition in clinical MPNST trials, particularly in patients with chr8 gain. The findings are not yet actionable in clinical practice and should prompt prospective human studies.
Mechanistic study with in vitro and PDX model evidence supporting a rational drug combination in a rare aggressive tumor, but lacks clinical trial data and human efficacy.
As stated by the source record.
Quoted from the source exactly as published.
This work provides preclinical justification for testing combined FAK/MEK inhibition in clinical MPNST trials, particularly in patients with chr8 gain. The findings are not yet actionable in clinical practice and should prompt prospective human studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Aneuploidy is a hallmark of cancer often associated with inferior prognosis. Copy number gains of chromosome 8 (chr8) are recurrent in multiple cancers, including breast, prostate, colorectal cancers, and sarcomas such as malignant peripheral nerve sheath tumors (MPNSTs). MPNSTs are aggressive, hard-to-treat sarcomas frequently linked to the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome. To investigate the role of chr8 gain in MPNST pathogenesis, we performed a CRISPR knockout screen and identified 58 essential genes on chr8, including PTK2, which encodes focal adhesion kinase (FAK). We evaluated FAK as a therapeutic target and tested small-molecule FAK inhibitors (FAKi) alone or combined with RAF/MEK inhibitors (RAF/MEKi), a class of agents relevant to NF1-deficient tumors with ERK pathway hyperactivation. Both pharmacological and genetic inhibition of FAK reduced MPNST cell proliferation in vitro and tumor growth in vivo. Combined FAKi and RAF/MEKi treatment further suppressed phosphorylation of FAK, STAT3, and AKT while increasing cleaved caspase-3 and PARP-1, indicating enhanced apoptosis. In MPNST patient-derived xenograft (PDX) models, combination therapy significantly reduced tumor growth, showing superior efficacy, particularly in chr8 gain MPNST-PDX. These results support FAK/RAF/MEK co-targeting as a promising therapeutic strategy for chr8 gain MPNST and related tumors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.